SEC Form 4 · accession 0001017491-18-000005
SEELOS THERAPEUTICS, INC. · SEEL
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Neil Morton
Officer — SVP, Chief Business Officer
Period of report
Jan 1, 2018
Accepted (ET)
Jan 3, 2018 · 7:45 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001017491
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Jan 1, 2018 | F | 2,194 | $1.84 | D | 145,831 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F2 | $2.11 | Jan 3, 2018 | A | 60,000 | A | — | Jan 3, 2028 | Common Stock | 60,000 | 60,000 | D |
Explanation of responses
- F1Represents shares forfeited by Reporting Person to cover certain tax liabilities incident to the vesting of the security.
- F2This option shall vest with respect to one-fourth of the underlying shares upon the first anniversary of the grant date, and then with respect to the remaining shares monthly thereafter over the next three years so the option will be fully vested as of 1/3/2022, subject to the Reporting Person's continued employment or service to the Issuer through such date.